Filing Summary
Business context and reporting period: Ascendis Pharma A/S filed this Form 6-K for September 2026. It reports the closing of an exercise window for outstanding warrants on September 29, 2026.
Key financial and capital metrics
- The Company issued 210,812 ordinary shares, each with nominal value DKK 1, following exercises of certain warrants.
- Average cash consideration was approximately $123.36 per share, based on the DKK-USD exchange rate on September 29, 2026. This implies approximate proceeds of $26.0 million; the filing does not state aggregate proceeds as a separate figure.
- Registered share capital increased by nominal DKK 210,812 to nominal DKK 66,400,738. The Company amended its articles of association accordingly.
- The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures.
Changes versus prior comparable period
The filing does not provide a prior-period comparison. It reports the share issuance and resulting increase in registered share capital.
Outlook, risks, and other items
No guidance, outlook, management commentary, or contingencies are disclosed. The report states that it is incorporated by reference into specified existing Form S-8 and Form F-3 registration statements. The amended articles of association are filed as Exhibit 1.1.
Facts investors should verify
- The total number and terms of warrants exercised, and any warrants remaining outstanding.
- Actual aggregate cash proceeds and the resulting share count on a fully diluted basis.
- The amended articles of association and its effect on the Company’s registered capital.